INVESTORS

Press Releases

 
Press Releases
  Date Title View
Nov 12, 2013
NEW HAVEN, Conn., Nov. 12, 2013 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today reported financial results for the three and nine months ended September 30, 2013 and provided an update on the Company's portfolio of direct-acting antiviral compounds being developed for the treatment of chronic hepatitis C virus (HCV). For...
PDF
Nov 11, 2013
NEW HAVEN, Conn., Nov. 11, 2013 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion, will present a corporate overview at the Credit Suisse Healthcare Conference on Wednesday, November 13, 2013 at 1:30 p.m. MT / 3:30 p.m. ET at The Phoenic...
PDF
Nov 2, 2013
NEW HAVEN, Conn., Nov. 2, 2013 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced a poster presentation detailing the preclinical profile of ACH-3422, a uridine-analog nucleotide prodrug being advanced for the potential treatment of chronic hepatitis C viral infection (HCV). The poster is being presented at the 64th A...
PDF
Sep 27, 2013
NEW HAVEN, Conn., Sept. 27, 2013 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today provided an update on development of compounds in its pipeline of therapies for the treatment of chronic hepatitis C virus, or HCV. Achillion today received a response from the U. S. Food and Drug Administration, or FDA, on the clinical hold rel...
PDF
Sep 6, 2013
NEW HAVEN, Conn., Sept. 6, 2013 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion, will present a corporate overview at two upcoming investor conferences: Morgan Stanley Global Healthcare Conference on Monday, September 9, 2013 at 3...
PDF
Aug 7, 2013
NEW HAVEN, Conn., Aug. 7, 2013 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today reported financial results for the three and six months ended June 30, 2013 and provided an update on the Company's portfolio of clinical stage compounds being developed for the treatment of the hepatitis C virus (HCV). For the second quarter ...
PDF
Jul 1, 2013
Following Phase 1 drug-drug interaction study with ritonavir-boosted atazanavir showing elevated liver enzymes, sovaprevir placed on clinical hold by FDAOngoing enrollment and treatment of patients remains unaffected in Phase 2 -007 combination trial evaluating 12-weeks of sovaprevir and ACH-3102 for treatment-naive genotype 1 patientsConference ca...
PDF
Jun 12, 2013
NEW HAVEN, Conn., June 12, 2013 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, President and Chief Executive Officer of Achillion, and members of the senior management team will present a corporate update and participate on a HCV Panel at the Wells Fargo 2013 Healthcare Conference on Tuesday...
PDF
May 30, 2013
— Advancement of ACH-3422 Complements Achillion's Portfolio of 2nd Generation Protease and NS5A Inhibitors Providing the Opportunity to Optimize Treatment Duration and Outcomes for All HCV Patients — — Conference Call and Webcast to be Hosted Today at 12:00pm EDT — NEW HAVEN, Conn., May 30, 2013 (GLOBE NEWSWIRE) -- Achi...
PDF
May 28, 2013
NEW HAVEN, Conn., May 28, 2013 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that President and Chief Executive Officer Michael D. Kishbauch has decided to retire. In conjunction with this decision, the Board has appointed President of Research and Development and Chief Scientific Officer, Milind Deshpande, Ph.D....
PDF
FirstPrevious
...
7
...
NextLast